Abstract 1587P
Background
The treatment and survival associated with multiple cancers has dramatically improved over the past decade with therapeutic advances. While print and broadcast media often report on cancer, it is unknown how movies depict cancer, treatment, or outcomes. Given that film may influence and shape public opinion, and potential willingness to seek out cancer treatment, we evaluated the portrayal of cancer in movies.
Methods
We searched for movies released between 2010 and 2020 using IMDb.com with search references for cancer in keywords. We excluded non-English language movies to avoid error in translation. We viewed and coded movies to include character’s role, diagnosis, curability, treatment, race/ethnicity, and gender. Per institutional policies, the study was not submitted for IRB approval because all data are publicly available.
Results
We identified 104 movies depicting cancer and oncologists between 2010 and 2020. A total of 108 characters with cancer were portrayed. Female characters were depicted more often (n = 60, 55.6%) than male characters (n = 48, 44.4%). The type of cancer was most often not specified in the movie (n = 40, 37%). The majority of characters were portrayed as having an incurable cancer (n = 70, 64.8%), while the curability of cancer was unknown in 21.3% of roles (n = 23). Only 13.9% of characters (n = 15) were depicted as having a curable cancer. The cancer-directed therapy was not specified or depicted for most characters (n = 37, 34.3%). When treatment was depicted or specified, chemotherapy was the most common treatment shown (n = 36, 33.3%). Two characters were depicted as choosing alternative medicine. Twelve characters were shown to choose forgoing cancer directed treatment. Zero characters (0%) were shown receiving immune checkpoint inhibitors or genomic-based therapies. Hospice or palliative care was discussed and offered for 8 characters (7.4%).
Conclusions
Most movies released from 2010 to 2020 with an oncology storyline do not contain granular details about cancer type or treatment. Most characters were portrayed as having an incurable malignancy. Chemotherapy was the most commonly depicted therapy while newer therapies were not depicted. The portrayal of oncology in recent English-language movies does not accurately reflect the reality of cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D.J. Benjamin: Financial Interests, Advisory Board: Astellas, Eisai, Seagen; Financial Interests, Speaker’s Bureau: Merck; Financial Interests, Other: Merck. A. Rezazadeh Kalebasty: Financial Interests, Personal, Advisory Board, advisory board and speaker: Exelixis, Bayer, Pfizer, Genentech, EMD Serono; Financial Interests, Personal, Advisory Board, speaker and advisory board: AstraZeneca, Novartis, BMS; Financial Interests, Personal, Invited Speaker: Janssen, Astellas Medivation, Pfizer, Novartis, Genentech/Roche, Eisai, AstraZeneca, BMS, Amgen, Exelixis, EMD Serono, Merck, Seattle Genetics/ Astellas, Myovant, Gilead Sciences; Financial Interests, Personal, Advisory Board: Gilead Sciences; Financial Interests, Institutional, Local PI: Genentech, Exelixis, Janssen, AstraZeneca, Bayer, BMS, Eisai, Macrogenics, Astellas, Beyond Spring, Bioclin Therapeutics, Clovis Oncology, Bavarian Nordic, Seattle Genetics, Immunomedics, Epizy, Arnivas, Navire, Point biopharma, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1553P - Access to EMA approved drugs in Europe, disparities across a border
Presenter: Orla Fitzpatrick
Session: Poster session 10
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10